Page Title
Clinical Trial Finder
Ask About Participating in This Study
Restore CFTR ProteinClosed to Enrollment
Study of ELX-02 in adults with cystic fibrosis who have at least one G542X mutation , protocol number Eloxx EL-012 - Cohorts 1 to 4The following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee entry into this particular study.
* indicates required field
Personal Information
Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).
(this will open in your email program)
Restore CFTR ProteinClosed to Enrollment
Study of ELX-02 in adults with cystic fibrosis who have at least one G542X mutation , protocol number Eloxx EL-012 - Cohorts 1 to 4
This study will look at the safety and tolerability of ELX-02 and how the body processes the drug, a molecule intended to restore CFTR function. Multiple doses of ELX-02 will be tested in adults with cystic fibrosis who have at least one G542X mutation.
-
Age:
18 Years and Older
-
Mutation(s):
No Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
15
-
Length of Participation:
15 weeks
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More